Document is current
Any future updates will be listed below
-
Authors
Morita, Satoru
Okabayashi, Koji
Endo, Yutaka
Kurebayashi, Yutaka
Masugi, Yohei
Abe, Tokiya
Hasegawa, Yasushi
Abe, Yuta
Kitago, Minoru
Seishima, Ryo
Shigeta, Kohei
Kitagawa, Yuko
- License Information
-
More Information
Article History
Received: 19 August 2025
Accepted: 25 December 2025
First Online: 27 January 2026
Disclosure
: For Yuko Kitagawa, relevant financial activities outside the submitted work involved, Chugai Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Asahi Kasei Pharma Corporation, Otsuka Pharmaceutical Co., Ltd., Kaken Pharmaceutical Co., Ltd., Sumitomo Pharma Co., Ltd., Kyouwa Kirin Co., Ltd., Kowa Company, Ltd., Asahi Kasei Pharma Corporation, AstraZeneca K.K., Ethicon Inc., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Factory, Inc., Olympus Corporation, Cardinal Health K.K., Shionogi & Co., Ltd., Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Bristol-Myers Squibb K.K., MSD K.K., Smith & Nephew K.K., Kaken Pharmaceutical Co., Ltd., ASKA Pharmaceutical Co., Ltd., Miyarisan Pharmaceutical Co. Ltd., Toray Industries, Inc., Daiichi Sankyo Company, Limited, Chugai Foundation for Innovative Drug, Discovery Science, Nippon Kayaku Co., Ltd., EA Pharma Co., Ltd., Intuitive Surgical G.K., Takeda Pharmaceutical Company Limited, Sysmex Corporation, Tsumura & Co., AI Medical Service Inc., Kowa Company, Ltd., Eisai Co., Ltd., Joint Research Laboratory for Development and Education of Innovative Medical Technology, Sysmex Corporation, and Medicaroid Corporation.
